节点文献

1例肺癌合并3级贫血患者应用贝伐珠单抗的药学监护

Pharmaceutical care on one patient with lung cancer and grade 3 anemia treated with bevacizumab

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 吴端仪曾卫强劳海燕何杏仪

【Author】 WU Duanyi;ZENG Weiqiang;LAO Haiyan;HE Xingyi;Department of Clinical Pharmacy, Shunde Hospital Guangzhou University of Chinese Medicine;Department of Pharmacy, Guangdong Provincial People’s Hospital/Guangdong Academy of Medical Sciences;

【通讯作者】 劳海燕;

【机构】 广州中医药大学顺德医院临床药学科广东省人民医院/广东省医学科学院药学部

【摘要】 识别和分析药物不良反应是临床药师工作的切入点之一。鉴于目前未见肺癌合并3级贫血患者使用贝伐珠单抗的安全性报道,本文报道1例临床药师对肺癌合并3级贫血患者使用贝伐珠单抗维持治疗的药学监护,为临床医师提供治疗参考。临床药师从药学的角度分析贝伐珠单抗的血液学毒性,并为患者提供全面的药学监护,促进合理用药。

【Abstract】 Adverse drug reaction identification and analysis is one of the entry points for clinical pharmacists. Since there is no report on the safety of bevacizumab used in patients with lung cancer and grade 3 anemia, here we reported a case of successful pharmaceutical care for a patient with lung cancer and grade 3 anemia during the maintenance treatment of bevacizumab, so as to provide a therapeutic reference for clinicians. The clinical pharmacist analyzed the hematotoxicity of bevacizumab from the perspective of pharmacy, gave patients comprehensive pharmaceutical care, and promoted rational drug using.

  • 【文献出处】 肿瘤药学 ,Anti-tumor Pharmacy , 编辑部邮箱 ,2021年06期
  • 【分类号】R969.3
  • 【被引频次】1
  • 【下载频次】156
节点文献中: 

本文链接的文献网络图示:

本文的引文网络